News - AMAG Pharmaceuticals, Incyte


Popular Filters

FDA cites insufficient information in response to AMAG’s Feraheme application

FDA cites insufficient information in response to AMAG’s Feraheme application


US drug company AMAG Pharmaceuticals (Nasdaq: AMAG) has received a complete response letter from the…

AMAG PharmaceuticalsFerahemeHematologyNephrology and HepatologyPharmaceuticalRegulationUSA

Herve Hoppenot quits Novartis to join Incyte

Herve Hoppenot quits Novartis to join Incyte


Swiss drug major Novartis said on Sunday (January 12), that Herve Hoppenot, president of Novartis Oncology,…


Incyte soars on positive mid-stage ruxolitinib trial results


Shares of US drug developer Incyte Corp (Nasdaq: INCY) leapt 21% to $32.55 in premarket trading yesterday…


Licensing deals between Xenon and Isis for XEN701, and Access and AMAG for MuGard


USA-based Isis Pharmaceuticals (Nasdaq: ISIS) revealed that privately-held Canadian firm Xenon Pharmaceuticals…

Access PharmaceuticalsAMAG PharmaceuticalsIsis PharmaceuticalsLicensingMuGardNephrology and HepatologyOncologyPharmaceuticalXEN701Xenon Pharmaceuticals

First myelofibrosis drug, Novartis' Jakavi, approved in Europe


Swiss drug major Novartis (NOVN: VX) received approval yesterday from the European Commission for Jakavi…

EuropeIncyteJakafiJakaviNovartisOncologyPharmaceuticalRare diseasesRegulation

Allos looks to complete merger with AMAG, as third party bows out


Allos Therapeutics (Nasdaq: ALTH) says that it continues to work with fellow USA-based AMAG Pharmaceuticals…

Allos TherapeuticsAMAG PharmaceuticalsMergers & AcquisitionsPharmaceutical

US FDA grants priority review as it accepts Incyte ruxolitinib NDA for myelofibrosis


The US Food and Drug Administration has accepted for filing the New Drug Application (NDA) for drug developer…

IncyteNorth AmericaNovartisOncologyPharmaceuticalRegulationruxolitinib

US deal for Vectura; takeover bid for AMAG


There was good news this morning from Vectura Group (LSE: VEC), a UK-based inhalation product development…

Allos TherapeuticsAMAG PharmaceuticalsLicensingMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryVectura

AMAG Pharma and Allos Thera to merge in $686 million stock deal; Express Scripts to buy Medco


US drugmakers AMAG Pharmaceuticals (Nasdaq: AMAG) and Allos Therapeutics (Nasdaq: ALTH) entered into…

Allos TherapeuticsAMAG PharmaceuticalsBiotechnologyMergers & AcquisitionsPharmaceutical

Back to top